Neoleukin revises CVR agreement with $500K de minimis threshold and unused lease holdback inclusion

Neurogene Inc.

Revised CVR Agreement adds a $500,000 de minimis threshold for CVR payments; unpaid amounts distributed by June 30, 2029.
100% of unused Lease Negotiation Holdback balance included in Gross Proceeds for CVR payments.
Amendment relates to the pending merger with Neurogene; closing expected under prior merger agreement.
CVR term ends June 30, 2029; payments made in cash or stock at company's discretion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.